| Sunburn and p53 in the onset of skin cancer A Ziegler, AS Jonason, DJ Leffellt, JA Simon, HW Sharma, J Kimmelman, ... Nature 372 (6508), 773-776, 1994 | 1855 | 1994 |
| Against pandemic research exceptionalism AJ London, J Kimmelman Science 368 (6490), 476-477, 2020 | 390 | 2020 |
| Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments VC Henderson, J Kimmelman, D Fergusson, JM Grimshaw, DG Hackam PLoS medicine 10 (7), e1001489, 2013 | 326 | 2013 |
| Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials B Carlisle, J Kimmelman, T Ramsay, N MacKinnon Clinical trials 12 (1), 77-83, 2015 | 321 | 2015 |
| The Ottawa statement on the ethical design and conduct of cluster randomized trials C Weijer, JM Grimshaw, MP Eccles, AD McRae, A White, JC Brehaut, ... PLoS medicine 9 (11), e1001346, 2012 | 295 | 2012 |
| Increasing placebo responses over time in US clinical trials of neuropathic pain AH Tuttle, S Tohyama, T Ramsay, J Kimmelman, P Schweinhardt, ... Pain 156 (12), 2616-2626, 2015 | 275 | 2015 |
| Distinguishing between exploratory and confirmatory preclinical research will improve translation J Kimmelman, JS Mogil, U Dirnagl PLoS biology 12 (5), e1001863, 2014 | 255 | 2014 |
| Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines GQ Daley, I Hyun, JF Apperley, RA Barker, N Benvenisty, AL Bredenoord, ... Stem cell reports 6 (6), 787-797, 2016 | 224 | 2016 |
| ISSCR guidelines for stem cell research and clinical translation: the 2021 update R Lovell-Badge, E Anthony, RA Barker, T Bubela, AH Brivanlou, ... Stem cell reports 16 (6), 1398-1408, 2021 | 219 | 2021 |
| Gene transfer and the ethics of first-in-human research: lost in translation J Kimmelman Cambridge University Press, 2010 | 152 | 2010 |
| The therapeutic misconception at 25: treatment, research, and confusion J Kimmelman Hastings Center Report 37 (6), 36-42, 2007 | 149 | 2007 |
| Confronting stem cell hype T Caulfield, D Sipp, CE Murry, GQ Daley, J Kimmelman Science 352 (6287), 776-777, 2016 | 145 | 2016 |
| Ethics of controlled human infection to address COVID-19 SK Shah, FG Miller, TC Darton, D Duenas, C Emerson, HF Lynch, ... Science 368 (6493), 832-834, 2020 | 133 | 2020 |
| The questionable use of unequal allocation in confirmatory trials SP Hey, J Kimmelman Neurology 82 (1), 77-79, 2014 | 125 | 2014 |
| Where have all the rodents gone? The effects of attrition in experimental research on cancer and stroke C Holman, SK Piper, U Grittner, AA Diamantaras, J Kimmelman, ... PLoS biology 14 (1), e1002331, 2016 | 124 | 2016 |
| Are outcome-adaptive allocation trials ethical? SP Hey, J Kimmelman Clinical trials 12 (2), 102-106, 2015 | 122 | 2015 |
| Recent developments in gene transfer: risk and ethics J Kimmelman Bmj 330 (7482), 79-82, 2005 | 112 | 2005 |
| The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews A Razaghizad, SB Windle, KB Filion, G Gore, I Kudrina, ... American journal of public health 111 (8), e1-e12, 2021 | 107 | 2021 |
| Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty J Kimmelman, AJ London PLoS medicine 8 (3), e1001010, 2011 | 107 | 2011 |
| Helsinki discords: FDA, ethics, and international drug trials J Kimmelman, C Weijer, EM Meslin The Lancet 373 (9657), 13-14, 2009 | 107 | 2009 |
Dean A FergussonSenior Scientist, Ottawa Hospital Research InstituteVerified email at ohri.ca
